Neuraptive Therapeutics

Neuraptive Therapeutics’ Groundbreaking Study Paves Way for Improved Peripheral Nerve Injury Treatment

WAYNE, PA — Neuraptive Therapeutics, Inc., a Pennsylvania-based biotech company, recently announced a major breakthrough in the treatment of peripheral nerve injuries. The firm’s successful demonstration of proof-of-concept in the …

Neuraptive Therapeutics’ Groundbreaking Study Paves Way for Improved Peripheral Nerve Injury Treatment Read More

Venatorx Pharmaceuticals

Venatorx Pharmaceuticals Strikes Deal with Menarini Group for Global Rights to Cefepime-Taniborbactam

MALVERN, PA — Venatorx Pharmaceuticals recently granted exclusive commercial rights to Italy’s Menarini Group for its novel antibiotic, cefepime-taniborbactam. The agreement extends to 96 countries in Europe, Latin America, Middle …

Venatorx Pharmaceuticals Strikes Deal with Menarini Group for Global Rights to Cefepime-Taniborbactam Read More
Aclaris Therapeutics

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence Read More


Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leader in dermatology therapeutics, announced a significant development in its ongoing research for innovative skin cancer treatments. The company confirmed …

Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy Read More

Ocugen

Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a Pennsylvania-based biopharmaceutical company, has scored a significant regulatory milestone this week with the U.S. Food and Drug Administration (FDA) granting Regenerative Medicine …

Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment Read More